©The Author(s) 2024.
World J Gastroenterol. Jun 28, 2024; 30(24): 3059-3075
Published online Jun 28, 2024. doi: 10.3748/wjg.v30.i24.3059
Published online Jun 28, 2024. doi: 10.3748/wjg.v30.i24.3059
Table 1 Clinicopathological characteristics, n (%)
| Variable | All patients | Training set | Validation set |
| Age (years), mean (± SD) | 59.05 (10.45) | 58.45 (10.38) | 60.48 (10.54) |
| Sex, | |||
| Male | 203 (69.8) | 144 (70.6) | 59 (67.8) |
| Female | 88 (30.2) | 60 (29.4) | 28 (32.2) |
| Body mass index (kg/m2), mean (SD) | 22.86 (3.22) | 22.95 (3.04) | 22.65 (3.63) |
| Radical resection | |||
| Yes | 274 (94.2) | 195 (95.6) | 79 (90.8) |
| No | 17 (5.8) | 9 (4.4) | 8 (9.2) |
| Primary tumor site | |||
| Upper 1/3 | 11 (3.7) | 8 (3.9) | 3 (3.4) |
| Middle 1/3 | 38 (13.1) | 28 (13.7) | 10 (11.5) |
| Low 1/3 | 208 (71.5) | 142 (69.7) | 66 (75.9) |
| Whole | 34 (11.7) | 26 (12.7) | 8 (9.2) |
| Borrmann type | |||
| Ⅰ | 32 (11.0) | 22 (10.8) | 10 (11.5) |
| Ⅱ | 87 (29.9) | 63 (30.9) | 24 (27.6) |
| Ⅲ | 153 (52.6) | 109 (53.4) | 44 (50.6) |
| Ⅳ | 19 (6.5) | 10 (4.9) | 9 (10.3) |
| Lymph node positivity | |||
| Yes | 138 (47.4) | 99 (48.5) | 39 (44.8) |
| No | 153 (52.6) | 105 (51.5) | 48 (55.2) |
| Tumor size | |||
| < 20 mm | 29 (10.0) | 18 (8.8) | 11 (12.6) |
| 20–50 mm | 124 (42.6) | 89 (43.6) | 35 (40.2) |
| > 50 mm | 138 (47.4) | 97 (47.6) | 41 (47.1) |
| Differentiation | |||
| Poor | 101 (34.7) | 72 (35.3) | 29 (33.3) |
| Moderate | 149 (51.2) | 106 (52.0) | 43 (49.4) |
| Well | 26 (8.9) | 19 (9.3) | 7 (8.0) |
| Unknown | 15 (5.2) | 7 (3.4) | 8 (9.3) |
| Lauren type | |||
| Intestinal | 143 (49.1) | 105 (51.5) | 38 (43.7) |
| Diffuse | 51 (17.5) | 35 (17.2) | 16 (18.4) |
| Mixed | 84 (28.9) | 58 (28.4) | 26 (29.9) |
| Unknown | 13 (4.5) | 6 (2.9) | 7 (8.0) |
| TNM stage | |||
| Ⅰ | 117 (40.2) | 81 (39.7) | 36 (41.4) |
| Ⅱ | 71 (24.4) | 53 (26.0) | 18 (20.7) |
| Ⅲ | 89 (30.6) | 62 (30.4) | 27 (31.0) |
| Ⅳ | 14 (4.8) | 8 (3.9) | 6 (6.9) |
| Carcinoembryonic antigen | |||
| < 1.97 ng/mL | 144 (49.5) | 107 (52.5) | 37 (42.5) |
| ≥ 1.97 ng/mL | 147 (50.9) | 97 (47.5) | 50 (57.5) |
| CA199 | |||
| < 10.19 U/L | 145 (49.8) | 103 (50.5) | 42 (48.3) |
| ≥ 10.19 U/L | 146 (50.2) | 101 (49.5) | 45 (51.7) |
| CA724 | |||
| < 2.17 U/L | 145 (49.8) | 106 (52.0) | 39 (44.8) |
| ≥ 2.17 U/L | 146 (50.2) | 98 (48.0) | 48 (55.2) |
| CA125II | |||
| < 10.21 U/L | 145 (49.8) | 102 (50.0) | 43 (49.4) |
| ≥ 10.21 U/L | 146 (50.2) | 102 (50.0) | 44 (50.6) |
| NLR, mean (SD) | 2.63 (2.98) | 2.62 (3.03) | 2.66 (2.87) |
| PLR, mean (SD) | 148.10 (7.47) | 149.64 (78.22) | 144.50 (68.87) |
| SII, mean (SD) | 668.08 (768.43) | 683.94 (796.04) | 630.89 (702.44) |
| SIRI, mean (SD) | 70.69 (29.36) | 70.05 (24.26) | 72.18 (38.93) |
| CD3(+) (%), mean (SD) | 70.91 (38.40) | 69.00 (9.31) | 75.41 (68.84) |
| CD3(+)CD4(+) (%), mean (SD) | 40.82 (8.67) | 40.79 (8.22) | 40.88 (9.69) |
| CD3(+)CD8(+) (%), mean (SD) | 23.42 (8.07) | 23.49 (8.02) | 23.24 (8.25) |
| CD4(+)/CD8(+), mean (SD) | 2.04 (1.08) | 1.99 (0.92) | 2.17 (1.37) |
| CD3(+)CD4(+)CD8(+) (%), mean (SD) | 0.54 (1.23) | 0.61 (1.44) | 0.36 (0.37) |
| CD19(+) (%), mean (SD) | 11.32 (4.71) | 11.68 (4.76) | 10.48 (4.51) |
| CD3(-)CD16(+)CD56(+) (%), mean (SD) | 16.72 (9.55) | 16.25 (8.34) | 17.83 (11.02) |
| CD3(+)CD16(+)CD56(+) (%), mean (SD) | 3.13 (4.34) | 3.26 (4.89) | 2.83 (2.63) |
- Citation: Ba ZC, Zhu XQ, Li ZG, Li YZ. Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer. World J Gastroenterol 2024; 30(24): 3059-3075
- URL: https://www.wjgnet.com/1007-9327/full/v30/i24/3059.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i24.3059